FGL2 and cancer: This work substantiates previous work from our laboratory demonstrating that the immunosuppressive cytokine, Fgl2, can bind FcγRIIB+CD8+ T cells in vitro (20) and provides evidence that this phenomenon occurs in vivo in the setting of cancer.